Aripiprazole in the treatment of the psychosis prodrome: An open-label pilot study

British Journal of Psychiatry

Volumn 191, Issue SUPPL. 51, 2007, Pages

  Woods, Scott W ^a,c   Tully, Elizabeth M ^b   Walsh, Barbara C ^a   Hawkins, Keith A ^a   Callahan, Jennifer L ^a   Cohen, Shuki J ^a   Mathalon, Daniel H ^a   Miller, Tandy J ^a   McGlashan, Thomas H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; CENTRAL STIMULANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; HYPNOTIC AGENT; LORAZEPAM; MOOD STABILIZER; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; AKATHISIA; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INCREASED APPETITE; INSOMNIA; IRRITABILITY; LIBIDO; MALE; MEMORY DISORDER; MORNING DOSAGE; NERVOUSNESS; NOSE CONGESTION; PATIENT COMPLIANCE; PSYCHOSIS; SALIVA; SCORING SYSTEM; SEDATION; SENSORY DYSFUNCTION; SIDE EFFECT; SWEATING; SYMPTOMATOLOGY; TREATMENT RESPONSE; COGNITION; DRUG ADMINISTRATION; DRUG EFFECT; NEUROPSYCHOLOGICAL TEST; PILOT STUDY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; SCHIZOTYPAL PERSONALITY DISORDER; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; COGNITION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; SCHIZOTYPAL PERSONALITY DISORDER; TREATMENT OUTCOME;

EID: 37249047375     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.191.51.s96     Document Type: Article

References (42)

1. Addington, D., Addington, J. & Schissel, B. (1990) A depression rating scale for schizophrenics. Schizophrenia Research, 3, 247-251.
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorderes (4th edn) (DSM-IV). APA.
3. Barnes, T. R. (1989) A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672-676.
4. Beck, A. T., Epstein, N. Brown, G., et al (1988) An inventory for measuring clinical anxiety: psychometric properties. Journal of Consulting & Clinical Psychology, 56, 893-897.
5. Birchwood, M., Smith, J., Cochrane, R., et al (1990) The Social Functioning Scale, The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. British Journal of Psychiatry, 157, 853-859.
6. Bleuler, E. (1911) Dementia Praecox or the Group of the Schizophrenias. International Universities Press.
7. Branch, P. R. (1975) Abnormal involuntary movement scale (AIMS). Early Clinical Drug Evaluation Unit Intercom, 4, 3-6.
8. Brown, D., McEvoy, J., Saha, A. R., et al (2003) Aripiprazole in patients with first episode schizophrenia. Schizophrenia Research, 60, 274.
9. Burris, K. D., Molski, T. F., Xu, C., et al (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Journal of Pharmacology and Experimental Therapeutics, 302, 381-389.
10. Cornblatt, B. A., Risch, N. J., Faris, G., et al (1988) The Continuous Performance Test Identical Pairs Version (CPT-IP). I. New findings about sustained attention in normal families. Psychiatry Research, 26, 223-238.
11. Falloon, I. R. H. (1992) Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry, 55, 4-15.
12. Findling, R., Blumer, J., Kauffman, R., et al (2004) Pharmacokinetic effects of aripiprazole in children and adolescents with conduct disorder. International Journal of Neuropsychopharmacology, 7, S440.
13. Fromm-Auch, D. & Yeudall, L. T. (1983) Normative data for the Halstead-Reitan Neuropsychological Tests. Journal of Cliical Neuropsychology, 5, 221-238.
14. Hall, R. C. (1995) Global assessment of functioning. A modified scale. Psychosomatics, 36, 267-275.
15. Hawkins, K. A. & Wexler, B. E. (1999) California Verbal Learning Test: practice effects in a schizophrenia sample. Schizophrenia Research, 39, 73-78.
16. Hawkins, K. A., Addington, J., Keefe, R. S. E., et al (2004a) Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophrenia Research, 67, 115-122.
17. Hawkins, K. A., Quintan, D., Miller, T. J., et al (2004b) Factorial structure of the scale of prodromal symptoms. Schizophrenia Research, 68, 339-347.
18. Hawkins, K. A., Dean, D. & Pearlson, G. D. (2004c) Alternative forms of the Rey Auditory Verbal Learning Test: a review. Behavioural Neurology, 15, 99-107.
19. Heaton, R. K., Chelune, G. J., Talley, J. L., et al (1993) Wisconsin Card Sorting Test, Manual. Psychological Assessment Resources.
20. Heinrichs, D. W., Hanlon, T. E. & Carpenter, W. T., Jr (1984) The Quality of Life Scale: an instrument for rating the schizophrenic deficity syndrome. Schizophrenia Bulletin, 10, 388-398.
21. Kern, R. S., Green, M. F., Cornblatt, B. A., et al (2006) The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology, 187, 312-320.
22. Levine, J. & Schooler, N. R. (1986) Strategies for analyzing side-effect data from SAFTEE - a workshop held Fall 1985 in Rockville, Maryland. Psychopharmacology Bulletin, 22, 343-381.
23. Marder, S. R., McQuade, R. D., Stock, E., et al (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Research, 61, 123-136.
24. McGlashan, T. H., Zipursky, R. B., Perkins, D., et al (2006) Randomized double-blind clinical trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry, 163, 790-799.
25. McGorry, P. D., Yung, A. F., Phillips, L. J., et al (2002) Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry, 59, 921-928.
26. Miller, T. J., McGlashan, T. H., Woods, S. W., et al (1999) Symptom assessment in schizophrenic prodromal states. Psychiatric Quarterly, 70, 273-287.
27. Miller, T. J., McGlashan, T. H., Rosen, J. L., et al (2002) Prospective diagnosis of the prodrome for schizophrenia: preliminary evidence of interrater reliability and predictive validity using operational criteria and a structured interview. American Journal of Psychiatry, 159, 863-865.
28. Miller, T. J., McGlashan, T. H., Rosen, J. L., et al (2003a) Prodromal assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: predictive validity, inter-rater reliability, and training to reliability. Schizophrenia Bulletin, 29, 703-715.
29. Miller, T. J., Zipursky, R. B., Perkins, D. O., et al (2003b) A randomized double blind clinical trial of olanzapine vs placebo in patients at risk for being prodromally symptomatic for psychosis: II. Baseline characteristics of the prodromal sample. Schizophrenia Research, 61, 19-30.
30. Morrison, A. P., French, P., Walford, L., et al (2004) Cognitive therapy for the prevention of psychosis in people at ultra-high risk. Randomized controlled trial. British Journal of Psychiatry, 185, 291-297.
31. Preda, A., Miller, T. J., Rosen, J. L., et al (2002) Treatment histories of patients with a syndrome putatively prodromal for schizophrenia. Psychiatric Services, 53, 342-344.
32. Rey, R. A. (1964) L'examen clinique en psychologique. Presses Universitaires de France.
33. Simpson, G. M. & Angus, J. W. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, Supplementum, 212, 11-19.
34. Spreen, O. & Benton, A. L. (1969) Neurosensory Center Comprehensive Examination for Aphasia (NCCEA). University of Victoria Neuropsychology Laboratory.
35. Spreen, O. & Strauss, E. (1998) A Compendium of Neuropsychological Tests: Administration, norms, and commentary (2nd edn). Oxford University Press.
36. Sullivan, H. S. (1927) The onset of schizophrenia. American Journal of Psychiatry, 7, 105-134.
37. Woods, S. W. (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry, 64, 663-667.
38. Woods, S. W., Miller, T. J. & McGlashan, T. H. (2001) The prodromal patient: both symptomatic and at risk. CNS Spectrums, 6, 223-232.
39. Woods, S. W., Breier, A., Zipursky, R. B., et al (2003) Randomized trial of olanzapine vs placebo in the symptomatic acute treatment of patients meeting criteria for the schizophrenic prodrome. Biological Psychiatry, 54, 453-464.
40. Woods, S. W., Gueorguieva, R. V., Baker, C. B., et al (2005) Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Archives of General Psychiatry, 62, 961-970.
41. Young, R. C., Biggs, J. T., Ziegler, V. E., et al (1978) A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry, 133, 429-435.
42. Yung, A. R., Phillips, L. J., McGorry, P. D., et al (1998) Prediction of psychosis. A step towards indicated prevention of schizophrenia. British Journal of Psychiatry 172 (suppl. 33), 14-20.